Graft Polymer (UK) PLC (GB:GPL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Graft Polymer (UK) Plc plans to rebrand as Solvonis Therapeutics Plc, aligning its identity with a strategic focus on mental health and substance use disorder treatments. The company highlights significant progress in its collaboration with Awakn, advancing new therapeutics for mental health with promising study results expected soon. This strategic shift and ongoing collaboration underscore Graft Polymer’s commitment to innovation in the biotech sector.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.